Nearly 30 generic drugmakers in Asia, Africa and the Middle East will make cheap versions of Merck & Co’s (MRK.N) COVID-19 pill, under a landmark U.N.-backed deal to give poorer nations wider access to a drug seen as a weapon in fighting the pandemic. Merck’s early greenlight to the production of its anti-viral pill molnupiravir Read More…
